Extended spectrum β-lactamase-producing Escherichia coli faecal carriage in Spanish travellers returning from tropical and subtropical countries  by Sole, M. et al.
Extended spectrum b-lactamase-producing
Escherichia coli faecal carriage in Spanish
travellers returning from tropical and
subtropical countries
M. Sole1, C. Pitart1, I. Oliveira1, A. Fabrega1, L. Mu~noz1,
I. Campo2, P. Salvador2, M. J. Alvarez-Martınez1,2, J. Gascon1,
F. Marco1,2 and J. Vila1,2
1) Barcelona Centre for International Health Research, (CRESIB), (Hospital
Clınic – University of Barcelona) and 2) Hospital Clinic, School of Medicine,
University of Barcelona, Barcelona, Spain
Abstract
The aim of this study was to investigate the prevalence of
extended-spectrum b-lactamase (ESBL) -producing Escherichia coli
in stool samples from 457 patients with travellers’ diarrhoea who
had travelled to tropical and subtropical countries. Ninety-seven
ESBL-producing E. coli strains were isolated from 17.9% of the
patients (82/457). CTX-M-15 was the most prevalent enzyme
(80%) and India was the most visited country and showed the
highest prevalence of positive samples (37.4%).
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Extended-spectrum b-lactamase (ESBL) production is the most
common mechanism of bacterial resistance to third-generation
cephalosporins. The ESBL-producing Enterobacteriaceae have
become an endemic problem worldwide during the last
decade, the CTX-M family being the most widespread.
International travel has been characterized as a risk factor
for both colonization and infection with extended-spectrum
cephalosporin-resistant as well as carbapenem-resistant iso-
lates [1–3], such as those carrying NDM-1 [4]. Many studies
have focused on the prevalence of faecal carriers within
speciﬁc countries, which, in 2007, was between 6.6% and 8.2%
in Spain and was most associated with the CTX-M-14 enzyme
[5,6]. However, studies addressing the faecal carriage of
ESBL-producing Enterobacteriaceae in travellers are scarce
[3,7–9]. The aim of this study was to investigate the prevalence
of ESBL-producing Escherichia coli in stool samples from
patients with travellers’ diarrhoea who had travelled to
tropical and subtropical countries.
Travellers with travellers’ diarrhoea attending the Tropical
Medicine Unit of the Hospital Clinic of Barcelona from March
2009 to July 2011 were analysed (n = 420). Travellers’
diarrhoea was deﬁned according to previously reported
criteria [10]. Additionally, travellers with travellers’ diarrhoea
who attended the Emergency Department of the Hospital
Clinic during the same period were also included (n = 37). In
all cases, a standardized questionnaire covering clinical and
epidemiological data was completed. All patients were fol-
lowed until complete resolution of the symptoms.
Stool samples were screened for cephalosporin-resistant
Enterobacteriaceae using chromogenic selective media (Chro-
mID ESBL, bioMerieux, Marcy l’Etoile, France). The chromo-
genic plates used were inoculated as soon as the sample
arrived at the laboratory in parallel with the inoculation of
other conventional media for stool analysis. If all of the growing
colonies had the same morphology and colour, only one colony
was selected, otherwise the different colonies observed were
picked up. The bacteria were identiﬁed by matrix-assisted laser
desorption ionization–time of ﬂight mass spectroscopy, and
only E. coli isolates were selected. ESBL production was further
conﬁrmed using the double-disc synergy test (ceftazidime and
cefotaxime with amoxicillin/clavulanic acid). Genes encoding
ESBL (blaTEM, blaSHV and blaCTX-M) were detected by PCR
ampliﬁcation and sequence analysis using previously described
conditions [11–13]. The ESBL-producing E. coli isolates were
classiﬁed into the phylogenetic groups A, B1, B2 and D by
multiplex PCR as previously reported [14]. The disc-diffusion
method was performed for b-lactams, ciproﬂoxacin, gentami-
cin and cotrimoxazole and interpreted applying the EUCAST
breakpoints published in 2011 (document V1.3 2011 http://
www.eucast.org/antimicrobial_susceptibility_testing/previous_
versions_of_tables/). Risk factor (travel destination) for acqui-
sition of ESBL-producing E. coli was calculated using a logistic
regression model. Categorical data were compared using the
Fisher’s exact test. All statistical analyses were performed using
STATA (Stata Statistical Software) version 13.1 (StataCorp.,
College Station, TX, USA). The level of signiﬁcance was
established at the 0.05 level.
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A total of 457 patients with travellers’ diarrhoea were
screened (268 women (58.6%) and 189 men (41.4%)): the
overall median age being 33 years (interquartile range 28–40).
The median trip duration was 20 days (interquartile range 14–
31; n = 433). Eighty-two patients (17.9%) were colonized with
97 ESBL-producing E. coli isolates: 13 patients had two isolates
and one patient had three isolates (Table 1). Among the 100
ESBL-encoding genes detected, the CTX-M family showed the
highest prevalence (91%): 87.9% were identiﬁed as CTX-M-15,
6.6% as CTX-M-14, 3.3% as CTX-M-27 and 2.2% as others.
The remaining nine genes (9%) belonged to the SHV type:
55.6% corresponded to SHV-12, 33.3% SHV-5 and 11.1%
SHV-27. In total, three isolates showed the presence of two
ESBL-encoding genes (Table 2). Statistical analysis showed a
signiﬁcantly increased percentage of acquiring a CTX-M group
one enzyme when returning from Asia (p 0.0003). In addition,
a high percentage (43.3%) of the cephalosporin-resistant
isolates also produced TEM-1.
Several studies performed in Sweden and Canada have
provided evidence that international travel is a risk factor for
ESBL carriage, raising the prevalence from 2.4–4% in non-trav-
ellers to 23–36% in international travellers [7–9]. Similarly, two
studies published in our country reported rates of 6.6% and
8.2% of ESBL colonization in non-travellers [5,6]. CTX-M-15 is
highly disseminated in most parts of the world whereas
CTX-M-14 predominates in Spain [5,15]. Although ESBL
colonization of patients with TD was not assessed before
foreign travel, according to these data it seems reasonable to
suggest that international travel is also a risk factor among the
Spanish population.
Antimicrobial susceptibility testing showed that all isolates
were resistant to penicillins, second-, third- and fourth-gener-
ation cephalosporins and monobactams. However, in the
presence of b-lactamase inhibitors, the levels of resistance
decreased: 53.6% of the isolates were resistant to amoxicillin–
clavulanic acid whereas only 3% of the isolates were resistant
to piperacillin–tazobactam. All isolates were susceptible to
carbapenems, except one that additionally harboured an
NDM-1 carbapenemase, as previously reported by our group
[4]. High percentages of resistance were also seen for other
antimicrobials: 49.5% of the isolates were resistant to genta-
micin, 79.4% to ciproﬂoxacin and 84.5% to cotrimoxazole.
Concerning the phylogenetic group, 58.8% of the isolates
belonged to phylogenetic groups A and B1 (52.6% and 6.2%,
respectively), and 41.2% to the potentially virulent phyloge-
netic groups D (26.8%) and B2 (14.4%).
Travel destination is likely to be a major factor for
ESBL-carriage positivity of faecal samples. Patients returning
from South Asia (particularly India and Thailand), and North
Africa (Egypt) are those usually most predisposed to become
carriers [7–9]. In this study, most of the patients (40.5%) had
travelled to the Asian continent, followed by 34.4% who had
visited Africa and lastly, 18.4% who had travelled to Central
and South America. The prevalence of ESBL faecal carriers was
the highest for those patients visiting Asia (29.2%), particularly
South Asia (Table 1), whereas lower values were obtained for
Africa (12.7%) and Central and South America (9.5%). By far,
India was the most visited country (131 patients) and showed
the highest prevalence (37.4%). However, none of the 16
patients returning from Thailand was positive for ESBL
carriage. For the African continent, Senegal, Morocco and
Egypt were the most visited countries with prevalences of
17.4%, 14.3% and 15.4%, respectively. Lastly, Mexico, Peru and
Guatemala, with respective prevalences of 14.3%, 18.2% and
23.1%, were the most visited destinations in Central and South
America. Comparison with endemic values is difﬁcult because
studies reporting the prevalences in tropical and subtropical
countries are scarce. Nonetheless, in India the prevalence of
such isolates obtained from any type of clinical specimen has
been assessed and ranges widely from 24% to 79%, showing
alarmingly high rates, which could promote ESBL dissemination
TABLE 1. Prevalence and risk factor for extended-spectrum
b-lactamase-producing Escherichia coli by geographical distri-
bution
Areas and
countries
Number of
patients
(%)
Colonized
patients
(%)
Odds
ratiob (95% CI) p-value
North Africa 40 (8.8) 5 (12.5) 0.81 0.31–2.07 <0.0001
Egypt 13 2
Morocco 21 3
East Africa 40 (8.8) 0 1.28 –
West Africa 63 (13.8) 10 (15.9) 0.89 (0.40–1.98)
Burkina Faso 7 1
Ghana 4 2
Mali 10 2
Nigeria 2 1
Senegal 23 4
Central Africa 14 (3.1) 3 (21.4) 1.28 (0.55–2.99)
Cameroon 6 1
Congo 2 1
Equatorial
Guinea
2 1
South Africa 9 (2) 2 (22.2) 1.34 (0.30–6.11)
Mozambique 7 2
Central America 41 (9) 4 (9.7) 0.64 (0.24–1.72)
Guatemala 11 2
Mexico 14 2
South America 43 (9.4) 4 (9.3) 0.48 (0.17–1.40)
Peru 13 3
Venezuela 2 1
Caribbean 21 (4.6) 0 1.28 –
Eastern Asia 3 (0.6) 0 1.28 –
South Asia 142 (31.1) 51 (35.9) 3.31 (1.82–6.01)
India 131 49
Nepal 9 2
South East Asia 40 (8.8) 3 (7.5) 0.38 (0.12–1.25)
Indonesia 8 1
Malaysia 4 1
Myanmar 1 1
Thailand 16 0
More than
one regiona
1 (0.2) 0 1.28 –
Total 457 82 (17.9)
aSouth Africa and South Asia.
bOdds ratio for deviations from the grand mean.
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worldwide [16,17]. The distribution of the prevalence and type
of the ESBLs isolated from colonized patients by geographical
areas is shown in Tables 1 and 2.
In conclusion, among the few studies reporting the prev-
alence of ESBL faecal carriage in patients with travellers’
diarrhoea, to our knowledge this is the ﬁrst study conducted in
Spain. A signiﬁcant population including 457 patients was
studied. ESBL-producing E. coli isolates were found in 17.9% of
the patients returning from tropical and subtropical countries.
As described previously, the most prevalent enzyme was
CTX-M-15 [7–9], thereby emphasizing its dissemination
worldwide [15]. Moreover, patients returning from India
showed the highest prevalence of colonization (37.4%). In this
study, the differences found in travel destinations and preva-
lences may reﬂect different international travel patterns for
the Spanish population.
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TABLE 2. Geographical distribution of extended-spectrum b-lactamase (ESBL) types from colonized patients
Areas and countries
ESBL-producing
Escherichia coli
ESBL
CTX-M group 1 CTX-M group 9 SHV
CTX-M-15 CTX-M-3 CTX-M-14 CTX-M-9 CTX-M-27 SHV-5 SHV-12 SHV-27
North Africa 6
Egypt 3 2 1
Morocco 3 1 1 1
East Africa 0
West Africa 10
Burkina Faso 1 1
Ghana 2 2
Mali 2 2
Nigeria 1 1
Senegal 4 3b 1 1b
Central Africa 3
Cameroon 1 1
Congo 1 1
Equatorial Guinea 1 1
South Africa 2
Mozambique 2 1 1
Central America 5
Guatemala 3 2 1
Mexico 2 1c 2c
South America 4
Peru 3 3
Venezuela 1 1
Caribbean 0
Eastern Asia 0
South Asia 64
India 62 57d 2 1 2 1d
Nepal 2 2
South East Asia 3
Indonesia 1 1
Malaysia 1 1
Myanmar 1 1
Thailand 0
More than one regiona 0
Total 97 80 1 6 1 3 3 5 1
aSouth Africa and South Asia.
bOne isolate harboured CTX-M-15 + SHV-12.
cOne isolate harboured CTX-M-15 + CTX-M-14.
dOne isolate harboured CTX-M-15 + SHV-27.
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